Tags

Type your tag names separated by a space and hit enter

The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
Thromb Haemost. 1995 Sep; 74(3):837-41.TH

Abstract

We have investigated the interrelationships of plasma PAI-1 activity, the PAI-1 4G/5G polymorphism and risk of myocardial infarction (MI) in the ECTIM study, a case-control study of MI based in Belfast, Lille, Strasbourg and Toulouse. Mean PAI-1 levels in cases were similar across all centres but in controls, levels in the French centres were significantly higher. Only in Belfast were PAIl1 levels higher in cases (11.7 AU/ml) than controls (10.5 AU/ml). The PAI-1 4G allele frequency was similar in cases and controls (0.55 and 0.54). In all groups, 4G homozygotes had the highest mean plasma PAI-1 level (4G4G vs 5G5G; cases overall: 14.2 vs 12.1AU/ml; controls overall: 15.0 vs 12.6AU/ml), with the heterozygotes generally intermediate. The data from Belfast are consistent with the literature implicating PAI-1 level as an MI risk factor. In ECTIM, the PAI-1 4G/5G polymorphism is not a genetic risk factor for MI but is associated with PAI-1 activity. Thus homozygosity for the 4G allele may predispose to elevated PAI-1 and impaired fibrinolysis, perhaps requiring interaction with other genetic or environmental factors to influence MI risk.

Authors+Show Affiliations

Ye S
Department of Medicine, University College London Medical School, UK.
Green FR
No affiliation info available
Scarabin PY
No affiliation info available
Nicaud V
No affiliation info available
Bara L
No affiliation info available
Dawson SJ
No affiliation info available
Humphries SE
No affiliation info available
Evans A
No affiliation info available
Luc G
No affiliation info available
Cambou JP
No affiliation info available

MeSH

AdultAllelesBase SequenceCase-Control StudiesFranceGenotypeHeterozygoteHomozygoteHumansMaleMiddle AgedMolecular Sequence DataMyocardial InfarctionNorthern IrelandPlasminogen Activator Inhibitor 1Polymorphism, GeneticPromoter Regions, GeneticRisk FactorsWorld Health Organization

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8571307

Citation

Ye, S, et al. "The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated With Differences in Plasma PAI-1 Activity but Not With Risk of Myocardial Infarction in the ECTIM Study. Etude CasTemoins De I'nfarctus Du Mycocarde." Thrombosis and Haemostasis, vol. 74, no. 3, 1995, pp. 837-41.
Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost. 1995;74(3):837-41.
Ye, S., Green, F. R., Scarabin, P. Y., Nicaud, V., Bara, L., Dawson, S. J., Humphries, S. E., Evans, A., Luc, G., & Cambou, J. P. (1995). The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thrombosis and Haemostasis, 74(3), 837-41.
Ye S, et al. The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated With Differences in Plasma PAI-1 Activity but Not With Risk of Myocardial Infarction in the ECTIM Study. Etude CasTemoins De I'nfarctus Du Mycocarde. Thromb Haemost. 1995;74(3):837-41. PubMed PMID: 8571307.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. A1 - Ye,S, AU - Green,F R, AU - Scarabin,P Y, AU - Nicaud,V, AU - Bara,L, AU - Dawson,S J, AU - Humphries,S E, AU - Evans,A, AU - Luc,G, AU - Cambou,J P, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 837 EP - 41 JF - Thrombosis and haemostasis JO - Thromb Haemost VL - 74 IS - 3 N2 - We have investigated the interrelationships of plasma PAI-1 activity, the PAI-1 4G/5G polymorphism and risk of myocardial infarction (MI) in the ECTIM study, a case-control study of MI based in Belfast, Lille, Strasbourg and Toulouse. Mean PAI-1 levels in cases were similar across all centres but in controls, levels in the French centres were significantly higher. Only in Belfast were PAIl1 levels higher in cases (11.7 AU/ml) than controls (10.5 AU/ml). The PAI-1 4G allele frequency was similar in cases and controls (0.55 and 0.54). In all groups, 4G homozygotes had the highest mean plasma PAI-1 level (4G4G vs 5G5G; cases overall: 14.2 vs 12.1AU/ml; controls overall: 15.0 vs 12.6AU/ml), with the heterozygotes generally intermediate. The data from Belfast are consistent with the literature implicating PAI-1 level as an MI risk factor. In ECTIM, the PAI-1 4G/5G polymorphism is not a genetic risk factor for MI but is associated with PAI-1 activity. Thus homozygosity for the 4G allele may predispose to elevated PAI-1 and impaired fibrinolysis, perhaps requiring interaction with other genetic or environmental factors to influence MI risk. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/8571307/The_4G/5G_genetic_polymorphism_in_the_promoter_of_the_plasminogen_activator_inhibitor_1__PAI_1__gene_is_associated_with_differences_in_plasma_PAI_1_activity_but_not_with_risk_of_myocardial_infarction_in_the_ECTIM_study__Etude_CasTemoins_de_I'nfarctus_du_Mycocarde_ L2 - http://www.diseaseinfosearch.org/result/8938 DB - PRIME DP - Unbound Medicine ER -